{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T10:22:37Z","timestamp":1781950957174,"version":"3.54.5"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,9]]},"DOI":"10.7759\/cureus.106725","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T16:06:21Z","timestamp":1775750781000},"source":"Crossref","is-referenced-by-count":1,"title":["New Diagnosis of B-cell Follicular Lymphoma Temporally Associated With Routine Vaccination: A Report of Two Cases"],"prefix":"10.7759","author":[{"given":"Tina","family":"Emami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debvarsha","family":"Mandal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chidalu Christabel","family":"Anyika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuf","family":"Salim Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lokesh","family":"Pendyala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad M","family":"Salim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0132-x","article-title":"Follicular lymphoma","volume":"5","author":"Carbone A","year":"2019","unstructured":"Carbone A, Roulland S, Gloghini A, Younes A, von Keudell G, L\u00f3pez-Guillermo A, Fitzgibbon J. Follicular lymphoma. Nat Rev Dis Primers. 2019, 5:83. 10.1038\/s41572-019-0132-x","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.3990","article-title":"Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa\/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource","volume":"31","author":"Link BK","year":"2013","unstructured":"Link BK, Maurer MJ, Nowakowski GS, et al.. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa\/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource. J Clin Oncol. 2013, 31:3272-8. 10.1200\/JCO.2012.48.3990","journal-title":"J Clin Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse large B-cell lymphoma","volume":"384","author":"Sehn LH","year":"2021","unstructured":"Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med. 2021, 384:842-58. 10.1056\/NEJMra2027612","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2021.03.041","article-title":"Follicular lymphoma: an update on diagnosis, prognosis, and management","volume":"157","author":"Mozas P","year":"2021","unstructured":"Mozas P, Sorigu\u00e9 M, L\u00f3pez-Guillermo A. Follicular lymphoma: an update on diagnosis, prognosis, and management. Med Clin (Barc). 2021, 157:440-8. 10.1016\/j.medcli.2021.03.041","journal-title":"Med Clin (Barc)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34408-0","article-title":"Single-cell profiling reveals a memory B cell-like subtype of follicular lymphoma with increased transformation risk","volume":"13","author":"Wang X","year":"2022","unstructured":"Wang X, Nissen M, Gracias D, et al.. Single-cell profiling reveals a memory B cell-like subtype of follicular lymphoma with increased transformation risk. Nat Commun. 2022, 13:6772. 10.1038\/s41467-022-34408-0","journal-title":"Nat Commun"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35378","article-title":"Early histological transformation of follicular lymphoma to diffuse large B-cell lymphoma indicating adverse survival: a population-based analysis and validation","volume":"130","author":"Li ZH","year":"2024","unstructured":"Li ZH, Zhang MY, Federico M, et al.. Early histological transformation of follicular lymphoma to diffuse large B-cell lymphoma indicating adverse survival: a population-based analysis and validation. Cancer. 2024, 130:3321-32. 10.1002\/cncr.35378","journal-title":"Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252313213","article-title":"A diagnostic approach in large B-cell lymphomas according to the Fifth World Health Organization and International Consensus Classifications and a Practical Algorithm in Routine Practice","volume":"25","author":"Zanelli M","year":"2024","unstructured":"Zanelli M, Sanguedolce F, Zizzo M, et al.. A diagnostic approach in large B-cell lymphomas according to the Fifth World Health Organization and International Consensus Classifications and a Practical Algorithm in Routine Practice. Int J Mol Sci. 2024, 25:13213. 10.3390\/ijms252313213","journal-title":"Int J Mol Sci"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.798095","article-title":"Rapid progression of angioimmunoblastic T cell lymphoma following BNT162b2 mRNA vaccine booster shot: a case report","volume":"8","author":"Goldman S","year":"2021","unstructured":"Goldman S, Bron D, Tousseyn T, et al.. Rapid progression of angioimmunoblastic T cell lymphoma following BNT162b2 mRNA vaccine booster shot: a case report. Front Med (Lausanne). 2021, 8:798095. 10.3389\/fmed.2021.798095","journal-title":"Front Med (Lausanne)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio R","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, et al.. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022, 36:1720-48. 10.1038\/s41375-022-01620-2","journal-title":"Leukemia"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1172\/JCI63186","article-title":"Pathogenesis of follicular lymphoma","volume":"122","author":"Kridel R","year":"2012","unstructured":"Kridel R, Sehn LH, Gascoyne RD. Pathogenesis of follicular lymphoma. J Clin Invest. 2012, 122:3424-31. 10.1172\/JCI63186","journal-title":"J Clin Invest"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.7163","article-title":"Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial","volume":"34","author":"Sarkozy C","year":"2016","unstructured":"Sarkozy C, Trneny M, Xerri L, et al.. Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial. J Clin Oncol. 2016, 34:2575-82. 10.1200\/JCO.2015.65.7163","journal-title":"J Clin Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"Campo E","year":"2022","unstructured":"Campo E, Jaffe ES, Cook JR, et al.. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood. 2022, 140:1229-53. 10.1182\/blood.2022015851","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05314-2","article-title":"Hypermetabolic lymphadenopathy following administration of BNT162b2 mRNA Covid-19 vaccine: incidence assessed by [(18)F]FDG PET-CT and relevance to study interpretation","volume":"48","author":"Cohen D","year":"2021","unstructured":"Cohen D, Krauthammer SH, Wolf I, Even-Sapir E. Hypermetabolic lymphadenopathy following administration of BNT162b2 mRNA Covid-19 vaccine: incidence assessed by [(18)F]FDG PET-CT and relevance to study interpretation. Eur J Nucl Med Mol Imaging. 2021, 48:1854-63. 10.1007\/s00259-021-05314-2","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-133587","article-title":"Etiologic heterogeneity among non-Hodgkin lymphoma subtypes","volume":"112","author":"Morton LM","year":"2008","unstructured":"Morton LM, Wang SS, Cozen W, et al.. Etiologic heterogeneity among non-Hodgkin lymphoma subtypes. Blood. 2008, 112:5150-60. 10.1182\/blood-2008-01-133587","journal-title":"Blood"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.01.027","article-title":"Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals","volume":"185","author":"Lederer K","year":"2022","unstructured":"Lederer K, Bettini E, Parvathaneni K, et al.. Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals. Cell. 2022, 185:1008-24.e15. 10.1016\/j.cell.2022.01.027","journal-title":"Cell"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1285168","article-title":"Case report: gene expression profiling of COVID-19 vaccination-related lymphadenopathies reveals evidence of a dominantly extrafollicular immune response","volume":"14","author":"Menter T","year":"2023","unstructured":"Menter T, Zinner CP, Berger CT, Went P, Tzankov A. Case report: gene expression profiling of COVID-19 vaccination-related lymphadenopathies reveals evidence of a dominantly extrafollicular immune response. Front Immunol. 2023, 14:1285168. 10.3389\/fimmu.2023.1285168","journal-title":"Front Immunol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01134-x","article-title":"Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities","volume":"14","author":"Liu Y","year":"2021","unstructured":"Liu Y, Zhou X, Wang X. Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities. J Hematol Oncol. 2021, 14:125. 10.1186\/s13045-021-01134-x","journal-title":"J Hematol Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.265","article-title":"Lymphadenopathy with florid lymphoid and Langerhans cell hyperplasia and hemophagocytosis mimicking lymphoma after COVID-19 mRNA vaccination","volume":"2","author":"Tintle S","year":"2021","unstructured":"Tintle S, Chen M. Lymphadenopathy with florid lymphoid and Langerhans cell hyperplasia and hemophagocytosis mimicking lymphoma after COVID-19 mRNA vaccination. EJHaem. 2021, 2:845-7. 10.1002\/jha2.265","journal-title":"EJHaem"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-022-03400-w","article-title":"Atypical follicular hyperplasia with light chain-restricted germinal centers after COVID-19 booster: a diagnostic pitfall","volume":"482","author":"Patil A","year":"2023","unstructured":"Patil A, Swerdlow SH, Lossos IS, Chapman JR. Atypical follicular hyperplasia with light chain-restricted germinal centers after COVID-19 booster: a diagnostic pitfall. Virchows Arch. 2023, 482:905-10. 10.1007\/s00428-022-03400-w","journal-title":"Virchows Arch"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde LE","year":"2022","unstructured":"Budde LE, Sehn LH, Matasar M, et al.. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 2022, 23:1055-65. 10.1016\/S1470-2045(22)00335-7","journal-title":"Lancet Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte","volume":"116","author":"Coiffier B","year":"2010","unstructured":"Coiffier B, Thieblemont C, Van Den Neste E, et al.. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010, 116:2040-5. 10.1182\/blood-2010-03-276246","journal-title":"Blood"},{"key":"ref22","article-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): B\u2011Cell Lymphomas. Version 2.2024","author":"National Comprehensive Cancer Network","year":"2024","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): B\u2011Cell Lymphomas. Version 2.2024. National Comprehensive Cancer Network, Fort Washington; 2024."},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv304","article-title":"Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26 Suppl 5","author":"Tilly H","year":"2015","unstructured":"Tilly H, Gomes da Silva M, Vitolo U, et al.. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015, 26 Suppl 5:v116-25. 10.1093\/annonc\/mdv304","journal-title":"Ann Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/427658-new-diagnosis-of-b-cell-follicular-lymphoma-temporally-associated-with-routine-vaccination-a-report-of-two-cases","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T16:06:22Z","timestamp":1775750782000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/427658-new-diagnosis-of-b-cell-follicular-lymphoma-temporally-associated-with-routine-vaccination-a-report-of-two-cases"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.106725","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,9]]}}}